Virtual Library
Start Your Search
L.F. Tapias
Author of
-
+
P1.05 - Poster Session with Presenters Present (ID 457)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.05-012 - The Impact of EGFR Mutations on the Prognosis of Patients with Resected Stage I Lung Adenocarcinoma (ID 4753)
14:30 - 14:30 | Author(s): L.F. Tapias
- Abstract
Background:
Recent studies have reported that epidermal growth factor receptor (EGFR) mutations are potential predictive factors for prognosis as well as for the response to the treatment of EGFR tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma. However, the prognostic role of EGFR mutations has not been well studied in treatment-naïve stage I lung adenocarcinoma. In this study, we evaluated the pure prognostic value of EGFR mutations in patients with stage I lung adenocarcinoma who underwent complete resection.
Methods:
We retrospectively reviewed the medical records of treatment-naïve patients who underwent complete resection of stage I lung adenocarcinoma between January 2008 and December 2014. Mutation testing was performed on resected tumor using multiplex (SNaP Shot) polymerase chain reaction assay. Survival curves were generated with Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards model was used for multivariate analysis.
Results:
Of 583 patients, 127 (21.8%) patients had EGFR-mutations. Median follow up period after surgery was 36.9 months (range: 0.1-95.8). Patients with EGFR mutations showed a better 5-year recurrence-free survival (RFS, 89.4% vs 77.8%, p=0.0053) and 5-year overall survival (OS, 99.1% vs 87.7%, p=0.0044) than those with EGFR wild-type (Figure). Multivariate analysis demonstrated that the presence of EGFR mutation (HR=0.4875, p=0.0388) and pathological stage 0 or IA (HR=0.4590, p=0.0016) were independent prognostic factors for better RFS. The presence of EGFR mutations (HR=0.1878, p=0.0443), lobar resection (HR=0.4076, p=0.0123), and ECOG performance status 0 (HR=0.4061, p=0.0259) were independent prognostic factors for better OS. Figure 1
Conclusion:
Patients harboring an EGFR-mutation in completely resected stage I lung adenocarcinoma had a much improved prognosis compared to those patients whose tumors expressed EGFR wild-type. The presence of an EGFR mutation was a significant positive prognostic factor in this cohort.
